TABLE 1

Failure, relapse and acquired drug resistance in new tuberculosis patients with isoniazid resistance without rifampicin resistance treated with the World Health Organization (WHO) new# regimen and in previously treated tuberculosis patients treated with the WHO re-treatment regimen

Pooled event rate+ (95% CI)
NewRe-treatment
Failure11% (6–17%)6% (2–10%)
Relapse10% (5–15%)5% (2–8%)
Acquired resistance8% (3–13%)3% (0–6%)
 Acquired resistance that is multidrug resistance98% (92–99%)71% (29–96%)

For treatment failure, pooled event rates did not differ significantly between those given the new and those given the re-treatment regimen. For relapse, pooled event rates differed significantly between those given the new and those given the re-treatment regimen (p=0.02). For acquired drug resistance, pooled event rates differed significantly between those given the new and those given the re-treatment regimen (p=0.02). #: WHO standard 6-month regimen for new tuberculosis patients (2HRZE/4HR); : WHO standard 8-month regimen for previously treated TB patients (2SHRZE/HRZE/5HRE); +: cumulative percentage associated with the outcome. Reproduced and modified from [9, tables 1 and 4] with permission from the publisher.